{"id":151196,"date":"2021-11-05T19:44:11","date_gmt":"2021-11-05T11:44:11","guid":{"rendered":"http:\/\/www.namnewsnetwork.org\/?p=151196"},"modified":"2021-11-05T19:44:11","modified_gmt":"2021-11-05T11:44:11","slug":"adagene-unveils-preclinical-data-from-two-transformative-antibody-programs-at-upcoming-american-society-of-hematology-ash-annual-meeting","status":"publish","type":"post","link":"http:\/\/namnewsnetwork.org\/?p=151196","title":{"rendered":"Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting"},"content":{"rendered":"\n<p><strong>SAN DIEGO and SUZHOU, China, Nov 5 (Bernama<strong>-GLOBE NEWSWIRE<\/strong>) &#8212; <\/strong>Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced publication of two abstracts featuring preclinical data from its expanding pipeline in advance of the 63rd ASH Annual Meeting &amp; Exposition.<\/p>\n\n\n\n<p>The preclinical results show compelling differentiation of ADG153, an anti-CD47 SAFEbody and ADG152, a CD20xCD3 POWERbody\u2122 integrating the company\u2019s proprietary bispecific T-cell engager (TCE) platform with SAFEbody masking technology. The full abstracts will be available on the <a rel=\"noreferrer noopener\" href=\"https:\/\/www.globenewswire.com\/Tracker?data=fV2j4mFXs09xKnNZQRiJ-msOhxNoEtxdXFsTG4YjjlDSbJWaDl_MCBLYXoZsvwsh82FAjH5eCFuGAnXOuj6kGnnHF3zjTHSdcoLSZjGK9JfjfJGf_c5jBjg8rlkaLNUONv-Zt29dKqO4TrycHwvISB2ZBm2HS0dUQm1qRWsInMHHd1vs4NjtnPmVNxOgUI7Zc8W7cZzW61Vg8AnZs7NRJQ==\" target=\"_blank\">ASH Annual Meeting and Exposition website<\/a> in anticipation of poster presentations at the hybrid meeting being held virtually and in Atlanta, Georgia from December 11-14, 2021. <\/p>\n\n\n\n<p><a href=\"http:\/\/mrem.bernama.com\/viewsm.php?idm=41500\">http:\/\/mrem.bernama.com\/viewsm.php?idm=41500<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO and SUZHOU, China, Nov 5 (Bernama-GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced publication of two abstracts featuring preclinical data from its expanding pipeline in advance of the 63rd ASH Annual Meeting &amp; Exposition. The [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[315],"tags":[],"_links":{"self":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/151196"}],"collection":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=151196"}],"version-history":[{"count":0,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=\/wp\/v2\/posts\/151196\/revisions"}],"wp:attachment":[{"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=151196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=151196"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/namnewsnetwork.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=151196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}